OncoMatch/Clinical Trials/NCT05417165
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Is NCT05417165 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pneumococcal 20-valent Conjugate Vaccine and Pneumococcal Polyvalent Vaccine for chronic lymphocytic leukemia.
Treatment: Pneumococcal 20-valent Conjugate Vaccine · Pneumococcal Polyvalent Vaccine — This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose of PSV23 after an interval of two months, followed by revaccination at 5 years). Giving patients frequent immunization as compared to 5 year immunization may result in higher protective titers in patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: chemotherapy
No prior therapy for CLL/SLL, including chemotherapy and/or radiotherapy is allowed
Cannot have received: radiation therapy
No prior therapy for CLL/SLL, including chemotherapy and/or radiotherapy is allowed
Cannot have received: anti-CD20 monoclonal antibody (rituximab)
having received rituximab within 6 months
Cannot have received: anti-CD20 monoclonal antibody (rituximab)
Exception: for non-hematological indications
received Rituximab or similar anti CD20 monoclonal antibody for non-hematological indications within 6 months
Cannot have received: intravenous immunoglobulin (IVIG)
Received intravenous immunoglobulin (IVIG) within 3 months prior to vaccination
Cannot have received: cellular therapy (CAR-T cells)
Patients who have received cellular therapy (e.g. CAR-T cells) within 12 months prior to vaccination
Cannot have received: stem cell transplant
History of allogenic stem cell transplantation
Cannot have received: pneumococcal vaccine
Patients who have previously received pneumococcal vaccine within the preceding 12 months
Lab requirements
Blood counts
neutropenic (granulocyte [PMN]s < 500 cells/mm^3) or absolute lymphocyte count less than 500 cells/mm^3 excluded
Patients with neutropenic (granulocyte [PMN]s < 500 cells/mm^3) or absolute lymphocyte count less than 500 cells/mm^3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify